Ryvu Therapeutics discovers and develops small molecule therapies that address high value emerging targets in oncology.

Our pipeline is built from internally-discovered candidates which make use of diverse therapeutic mechanisms, including programs directed at targets in the areas of transcriptional regulation, synthetic lethality, immuno-oncology and immunometabolism.

Ryvu’s two most advanced programs are currently in clinical trials. SEL120 is a selective CDK8 kinase inhibitor in clinical development for the treatment of acute myeloid leukemia and high-risk myelodysplastic syndromes.

SEL24/MEN1703 is a dual PIM/FLT3 kinase inhibitor in clinical development for the treatment of acute myeloid leukemia. Additional programs include candidates directed at SMARCA2/BRM, adenosine A2A/A2B receptor targets and STING agonists.

  • Clinical
  • Immuno-oncology
    & Immunometabolism
  • Synthetic


SEL120 SEL24/

Clinical Projects

  • SEL120

    CDK8 is a kinase submodule of the mediator complex, involved in both transcriptional activation and repression. CDK8- mediator complex integrates basal transcriptional machinery with the activity of oncogenic transcriptional and epigenetic factors. Targeting CDK8 and...

  • SEL24/MEN1703

    SEL24/MEN1703 is a selective, dual inhibitor of PIM and FLT3 kinases, two enzymes that are strongly implicated in malignant transformation of hematopoietic cells. The compound is a novel small molecule discovered by Ryvu and currently...

Immuno-oncology & Immunometabolism

Ryvu Therapeutics has deep expertise in the discovery of small molecule candidates with optimized properties to address specific limitations of existing therapeutic approaches.

To identify these candidates, Ryvu uses platforms based on the most current understanding of how the immune system interacts with cancer cells and how cancer cells function biologically. These immuno-oncology and immunometabolism approaches have a successful history in biopharmaceutical development. Ryvu has accumulated scientific and technical infrastructure that allow high-throughput generation of candidates using these platforms.


    STING protein is one of the major players in innate immune activation being a potent trigger of type I interferon (IFN) and pro-inflammatory cytokines. STING agonists facilitate cancer antigen recognition specific to individual patient and...


    The high therapeutic potential of HPK1 inhibitors (hematopoietic progenitor kinase 1, MAP4K1) lies in their potential to simultaneously improve T cell function, tumor antigen presentation and combat the immunosuppressive tumor microenvironment.  HPK1 is a negative...

Synthetic Lethality

One of the challenges in the development of new oncology therapeutics is the limited number of protein targets known to be addressable with small molecules. Synthetic lethality allows the identification of novel protein targets and mechanisms of cancer cell sensitivity that can be used therapeutically.

Compounds active on specific synthetic lethal targets selectively kill tumor cells of a precisely defined model system, characterized by a specific genetic, epigenetic or metabolic characteristic. This is the approach actively investigated at Ryvu that allows the generation of compounds with highly specific and well-characterized activity.


    Deletion of 9p21 locus is one of the most frequent genetic alterations associated with human cancers. Apart from tumor suppressor p16, locus 9p21 contains the gene coding methylthioadenosine phosphorylase (MTAP), the only enzyme capable of...

Novel Targets

Beyond publicly disclosed programs, Ryvu is working on candidates that address novel targets in the areas of synthetic lethality, immuno-oncology and immunometabolism to generate new therapeutics with first-in-class or best-in-class potential.

For the candidates, Ryvu is utilizing a proprietary drug discovery approach combining internally developed expertise and new sophisticated tools and technologies to identify small molecule compounds with favorable profiles and activity.

Discovery Collaborations

In April 2020, Ryvu Therapeutics and Galapagos have entered into a collaboration focused on the discovery and development of novel small molecule drugs in inflammation.
The collaboration is based on a novel drug target identified by Ryvu, which will contribute its technology platform and related intellectual property. Ryvu and Galapagos will both provide resources to support the collaboration and make use of their expertise in high-throughput screening, biology, medicinal chemistry, and toxicology.
During the joint research collaboration, Ryvu is responsible for early drug discovery and Galapagos will be responsible for all further development of the program.

In 2013, Ryvu and Merck KGaA initiated a joint research strategy involving intensive work on multiple targets and several chemical series. The collaboration has successfully completed two milestones and has been expanded over time with additional targets.
The aim of the partnership with Merck is the development of new anticancer therapeutics acting on diverse biological targets associated with aberrant metabolic pathways in cancer cells. Dependence on specific metabolic pathways is a feature of various types of cancer, therefore, targeting this vulnerability has many potential applications in a broad range of patient populations.
The collaboration has resulted in scientific achievements, the joint filing of patent applications and data presentations at international scientific conferences.


AACR Virtual Annual Meeting II, June 22-24, 2020

  • "Synergistic effect of CDK8 and BCL-2 inhibition in AML through regulation of MCL-1 and BIM balance"

    PDF Download
  • "In vivo and in vitro characterization of RVU330 best-in-class dual A2A/A2B adenosine receptor antagonist"

    PDF Download
  • "Development of selective small molecule STING agonists suitable for systemic administration"

    PDF Download
  • "Development and characterization of small molecule HPK1 inhibitors"

    PDF Download
  • "Development of novel, selective SMARCA2 (BRM) degraders for treatment of SMARCA4 (BRG1) mutated tumors"

    PDF Download

Virtual 25th Annual European Hematology Association (EHA) Congress, June 11-21, 2020

  • “A First-in-human study of SEL120, a novel oral selective CDK8/19 inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome”

    PDF Download
  • "Results of the dose escalation part of DIAMOND trial (CLI24-001): first in human study of SEL24/MEN1703, a dual PIM/FLT3 kinase inhibitor, in Patients with Acute Myeloid Leukemia"

    PDF Download

Synthetically Lethal Interactions of Heme Oxygenase-1 and Fumarate Hydratase Genes, Biomolecules 2020

  • Podkalicka, P.; Mucha, O.; Kruczek, S.; Biela, A.; Andrysiak, K.; Stępniewski, J.; Mikulski, M.; Gałęzowski, M.; Sitarz, K.; Brzózka, K.; Józkowicz, A.; Dulak, J.; Łoboda, A. Synthetically Lethal Interactions of Heme Oxygenase-1 and Fumarate Hydratase Genes. Biomolecules 2020, 10, 143.

    PDF Download

61st American Society of Hematology (ASH) Annual Meeting, December 7-10, 2019, Orlando, FL, USA

  • "SEL120 – a First-in-Class CDK8/19 Inhibitor As a Novel Option for the Treatment of Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome – Data from Preclinical Studies and Introduction to a Phase Ib Clinical Trial"

    PDF Download
  • "CDK8 Inhibitors Induce Transcriptional Reprogramming of AML Cells Associated with Differentiation"

    PDF Download